Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally

Rabies Clinical Trial

Official title:

A Cross-over, Open-label, Randomized Study Evaluating the Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S on Healthy Vietnamese Volunteers With 3 Doses of Pre-exposure Prophylaxis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05937113
• Other study ID #: VX.2019.02
• Status: Completed
• Phase: Phase 4
• Start date: June 13, 2020
• Est. completion date: October 30, 2020

Study information

• Verified date: July 2023
• Source: Vietnam Military Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, open-label, prospective, before-and-after comparison study in the same group.

Subjects suitable for the study will be randomly assigned at a ratio of 1:1 (block 4) to use the study vaccine by one of two routes of administration: Intramuscular or Intramuscular. Previously-unvaccinated subjects receive three injections of vaccine on day 0, 7 and 21-28. The aim of the study is to evaluate the safety and immunogenicity of the inactivated rabies vaccine RABIVAX-S administered intramuscularly and intradermally according to a 3-dose regimen in healthy volunteers.

Description:

1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).

Pre-exposure prophylaxis regimens for two groups

• Intramuscular 1ml on days D0, D7 and D21-28

• Intradermal injection 0.1 ml on days D0, D7 and D21-28

Randomization was performed according to two age stratifications:

• Stratification of research subjects from 5-15 years old

• Stratification of research subjects from 16-60 years old Population selected research subjects in the community in Dong Hung district, Thai Binh province

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: October 30, 2020
• Est. primary completion date: July 2, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 5 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Healthy volunteers aged 5-60 years at the time of study screening.

2. Consent to participate in the study by signing the consent to participate in the study after being provided with complete information about the study. The participation of research subjects under the age of 18 years will be signed by the legal guardian.

3. Research subjects with normal health are determined according to personal medical history, clinical examination and laboratory tests within the clinically acceptable normal range.

4. Able to follow the research process as assessed by the researcher.

5. Women of reproductive age who have been using effective contraception for at least 4 weeks prior to screening and are willing to continue contraception until at least 4 weeks after the last dose of the study vaccine together. Men participating in the study agreed not to conceive until at least 4 weeks after the last dose of the study vaccine.

Exclusion Criteria:

1. Subject is participating in any other clinical trial.

2. Research facility staff working directly in this study and their families and relatives. Family, relatives are defined as spouses, parents, children or siblings, whether adopted or legally adopted.

3. History of previous rabies vaccination (pre- or post-exposure regimen)

4. Have received rabies immunoglobulin (human/equine) in the past.

5. Fever (temperature =37°C) or moderate or severe acute illness, or infection on the day of vaccination.

6. History of systemic hypersensitivity reaction to any vaccine component or history of life-threatening reaction to an experimental vaccine or a vaccine containing any vaccine-like substance study.

7. Have received any immunoglobulin, blood, or blood-based product therapy in the past 3 months, which may interfere with the assessment of immune response.

8. Known seropositive status for HIV antibody, HCV antibody or hepatitis B surface antigen (HBsAg) (retest not required).

9. Receive any vaccine in the 4 weeks before the first trial vaccine

10. Expect to receive any vaccine for 4 weeks after the trial vaccine is administered.

11. Women who are pregnant or have a positive urine test or are not willing to use safe methods of contraception

12. Women who are breastfeeding

13. Participated in a clinical trial study within the past 3 months.

14. Have a plan to donate blood while participating in the study

15. History of or current drug or alcohol abuse within the past year.

16. Congenital or acquired immunodeficiency, immunosuppressive therapy such as antineoplastic chemotherapy or radiation within the previous 6 months, or long-term systemic corticosteroid therapy (Permission to use topical steroid/medication)

17. Thrombocytopenia, bleeding disorders or anticoagulants in the 3 weeks prior to vaccination is contraindicated intramuscularly (IM)

18. Subjects at high risk of exposure to rabies during the study period, for example veterinary surgeons (including students at veterinary colleges), technical staff working with doctors veterinarians, laboratory staff handling rabies-contaminated material, abattoir staff, zoo staff.

19. Subject plans to have surgery in the next 3 months.

20. Subjects using antimalarial drugs concurrently

21. Clinically significant acute or chronic conditions such as pulmonary, endocrine, autoimmune, psychiatric, cardiovascular, liver or renal disease, as determined by medical history and physical examination and in the opinion of the researcher may affect the objectives of the study.

22. Any other condition that, in the opinion of the researcher as a member, would jeopardize the safety or rights of the subject or prevent the subject from completing the protocol procedures study.

Related Conditions & MeSH terms

• Rabies

Intervention

Biological:
• RABIVAX-S
1 ml dose vaccine containing = 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with ß propiolactone). Pre-exposure prophylaxis regimens for two groups Intramuscular 1ml on days D0, D7 and D21+7 Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28

Locations

Country	Name	City	State
Vietnam	CDC Thai Binh	Thai Binh

Sponsors (2)

Lead Sponsor	Collaborator
Vietnam Military Medical University	Vabiotech

Country where clinical trial is conducted

Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Subjects Experiencing Solicited Local and Systemic Adverse Events (AE) after	Solicited local and systemic AEs were assessed by study staff in 30 minutes after vaccination.	Within 30 minutes of each vaccination
Primary	Rate of Subjects Experiencing Solicited Local and Systemic Adverse Events (AE)	Solicited local AEs were assessed by study staff 30 minutes after vaccination then daily for 7 days	within 7 days (day 1 to 7) of each vaccination and within 21 day after the first vaccination
Primary	Rate of Subjects Experiencing Unsolicited Adverse Events (AE)	Unsolicited AEs were observed by study staff while the subject is at a clinic for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a "solicited AE" (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination was to be recorded as an unsolicited AE	during 21 days after the third vaccination
Primary	Rate of Subjects Experiencing Unsolicited Serious Adverse Events (SAE)	A serious adverse event (SAE) is defined as an AE that meets one of the following conditions: Deadly. Life-threatening. Requires inpatient hospital admission or extended stay in hospital. Causes birth defects. Causes permanent or permanent injury or disability. Critical medical events that may not be fatal, not life-threatening, or require inpatient treatment will be considered a SAE if it is judged by professional judgment that the incident would be potentially dangerous. subject's health and the need for medical or surgical intervention to prevent one of the aforementioned consequences	Day 1 to Day 42
Secondary	Rate of Subjects With Seroconversion of rabies virus neutralizing antibody (RVNA) for Vaccine Antigens for subgroup of subjects	Serum specimens were tested for the presence and titer of rabies virus neutralizing antibody (RVNA) and the seroprotection rate was RVNA titer =0.5 IU/mL	Day 0, day 7, day 21 and day 42
Secondary	Geometric Mean Titer (GMT) of rabies virus neutralizing antibody (RVNA) for Vaccine Antigens at Baseline and Day 22 or 49 after vaccination (depending on age group) for each antigenic component of the vaccine	Serum specimens during Phase 3 were tested for the presence and titer of RVNA	Day 0, day 7, day 21 and day 42